Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Core Viewpoint - Merck is restructuring its human-health business into two divisions to mitigate the impact of the impending patent loss of its leading drug, Keytruda [1] Group 1: Business Restructuring - Merck will create a separate division for its cancer drugs, which will include Keytruda [1] - The other division will focus on non-cancer products [1] Group 2: Market Context - The restructuring is a strategic response to the pressures associated with the patent expiration of Keytruda, which is Merck's top-selling drug [1]